1253 Results

People

  1. Motzer
    Motzer
  2. Kingham
    Kingham
  3. Hudis
    Hudis
  4. Abou-Alfa
    Abou-Alfa
  5. Horwitz
    Horwitz
  6. Zelenetz
    Zelenetz
  7. Kris
    Kris
  8. Perales
    Perales
  9. Aghajanian
    Aghajanian
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (680)
  2. Solid Tumor Oncology Division (431)
  3. Hematologic Malignancies, Division of (230)
  4. Surgery (201)
  5. Center for Hematologic Malignancies (186)
  6. Survivorship Research (182)
  7. Population Sciences Research Program (170)
  8. Epidemiology and Biostatistics (122)
  9. Center for Pancreatic Cancer Research (110)
  10. Genitourinary Oncology Service (109)
  1. "multicenter study"
Formats
  1. Journal Article (1219)
  2. Research Letter (12)
  3. Conference Paper (7)
  4. Correspondence (6)
  5. Review (5)
  6. Guidelines (2)
  7. Editorial (1)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (680)
  2. Solid Tumor Oncology Division (431)
  3. Hematologic Malignancies, Division of (230)
  4. Surgery (201)
  5. Center for Hematologic Malignancies (186)
  6. Survivorship Research (182)

More Groups

People
  1. Robert Motzer (47)
  2. T Peter Kingham (31)
  3. Clifford Hudis (19)
  4. Andrew Zelenetz (18)
  5. Ghassan Abou-Alfa (18)
  6. Steven Horwitz (18)

More People

Years
  1. 2025 (86)
  2. 2024 (191)
  3. 2023 (130)
  4. 2022 (83)
  5. 2021 (50)
  6. 2020 (63)

More Years

Publications
  1. Journal of Clinical Oncology (118)
  2. Lancet Oncology (57)
  3. New England Journal of Medicine (56)
  4. Clinical Cancer Research (46)
  5. Blood (44)
  6. Cancer (36)

More Publications

Publishers
  1. Elsevier Inc. (152)
  2. Elsevier Science, Inc. (137)
  3. American Society of Clinical Oncology (124)
  4. Springer (84)
  5. Oxford University Press (79)
  6. Wiley Blackwell (71)

More Publishers

Results (1253)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
    Journal Article

    Choueiri, T. K.; Motzer, R. J.; Rini, B. I.; Haanen, J.; Campbell, M. T.; Venugopal, B.; Kollmannsberger, C.; Gravis-Mescam, G.; Uemura, M.; Lee, J. L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Patient experiences with avelumab in treatment-naïve metastatic Merkel cell carcinoma: Longitudinal qualitative interview findings from JAVELIN Merkel 200, a registrational clinical trial
    Journal Article

    Lambert, J.; Marrel, A.; D’Angelo, S. P.; Burgess, M. A.; Chmielowski, B.; Fazio, N.; Gambichler, T.; Grob, J. J.; Lebbé, C.; Robert, C.; more...
    The Patient: Patient-Centered Outcomes Research (2020)

    Fulltext@MSK | Save
  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: A randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Journal Article

    Landgren, C. O.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P.; Estell, J. A.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; more...
    Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Abou-Alfa, G. K.; Macarulla, T.; Javle, M. M.; Kelley, R. K.; Lubner, S. J.; Adeva, J.; Cleary, J. M.; Catenacci, D. V.; Borad, M. J.; Bridgewater, J.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): An open-label, single-arm, phase 3 trial
    Journal Article

    Kleinmann, N.; Matin, S. F.; Pierorazio, P. M.; Gore, J. L.; Shabsigh, A.; Hu, B.; Chamie, K.; Godoy, G.; Hubosky, S.; Rivera, M.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial
    Journal Article

    Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J. F.; Troso-Sandoval, T. A.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R.; Chan, A.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study
    Journal Article

    Dimopoulos, M.; Quach, H.; Mateos, M. V.; Landgren, O.; Leleu, X.; Siegel, D.; Weisel, K.; Yang, H.; Klippel, Z.; Zahlten-Kumeli, A.; more...
    Lancet (2020)

    Fulltext@MSK | Save
  • Reduced ceftazidime-avibactam susceptibility in KPC-producing Klebsiella pneumoniae from patients without ceftazidime-avibactam use history – A multicenter study in China
    Journal Article

    Cui, X.; Shan, B.; Zhang, X.; Qu, F.; Jia, W.; Huang, B.; Yu, H.; Tang, Y. W.; Chen, L.; Du, H.
    Frontiers in Microbiology (2020)

    Fulltext@MSK | Save
  • #EBUSTwitter: Novel use of social media for conception, coordination, and completion of an international, multicenter pathology study
    Journal Article

    Lepe, M.; Oltulu, P.; Canepa, M.; Wu, R. I.; Deeken, A.; Alex, D.; Dinares, C.; Doxtader, E. E.; Fitzhugh, V. A.; Gibier, J. B.; more...
    Archives of Pathology & Laboratory Medicine (2020)

    Fulltext@MSK | Save
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
    Journal Article

    Goldberg, A. D.; Atallah, E.; Rizzieri, D.; Walter, R. B.; Chung, K. Y.; Spira, A.; Stock, W.; Tallman, M. S.; Cruz, H. G.; Boni, J.; more...
    Leukemia Research (2020)

    Fulltext@MSK | Save